Ischemic Heart Disease (IHD) Drugs Industry Insights: Market Forecast to 2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Ischemic Heart Disease (IHD) Drugs Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The ischemic heart disease (IHD) drugs market size has demonstrated consistent expansion in recent years. This market is projected to increase from $6.36 billion in 2024 to $6.65 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.5%. The expansion witnessed historically can be linked to factors such as the increasing worldwide prevalence of ischemic heart disease, enhanced awareness and diagnostic capabilities, evolving lifestyle and dietary patterns, government initiatives aimed at cardiovascular health, partnerships for clinical trials, and existing insurance coverage and reimbursement policies.
The ischemic heart disease (IHD) drugs market size is predicted to show steady expansion in the coming years. It is projected to increase to “$7.7 billion in 2029, achieving a compound annual growth rate (CAGR) of 3.7%.” This growth during the forecast period can be attributed to factors such as an aging demographic, personalized medicine strategies, a strong emphasis on cardiovascular disease prevention, global health policies and initiatives, and international research collaborations. Significant trends anticipated in this period include a shift towards precision medicine approaches, a focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, the integration of anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Which Factors And Drivers Are Influencing The Ischemic Heart Disease (IHD) Drugs Market In 2025?
The expansion of the ischemic heart disease (IHD) drugs market is anticipated due to the increasing incidence of obesity and diabetes. Diabetes is a chronic metabolic condition marked by elevated blood glucose, while obesity is a medical state involving an excessive build-up of body fat, which can be detrimental to health. Individuals with obesity and diabetes frequently utilize ischemic heart disease drugs to address cardiovascular risk factors like high blood pressure and abnormal lipid levels, thereby lowering the probability of ischemic heart disease. For instance, a report from 2022 by the World Obesity Federation, a UK-based organization dedicated to combating obesity worldwide, projected that by 2030, one billion people globally, comprising 1 in 5 women and 1 in 7 men, will be living with obesity. Additionally, in June 2024, the UK’s National Health Service (NHS) disclosed that in 2023, they identified an additional 549,000 individuals in England at risk of type 2 diabetes. This increased the total number of people with pre-diabetes registered with a GP to 3,615,330, a substantial increase compared to 3,065,825 in 2022, marking a rise of nearly 20%. Consequently, the rising occurrence of obesity and diabetes is a key factor propelling the growth of the ischemic heart disease (IHD) drugs market.
What Are The Different Segment Classifications Within The Ischemic Heart Disease (IHD) Drugs Market?
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Which Ongoing Trends Are Expected To Shape The Ischemic Heart Disease (IHD) Drugs Market Outlook?
Companies engaged in the ischemic heart disease (IHD) drugs market are intensifying their efforts to develop cutting-edge myosin inhibitors, aiming to secure a competitive advantage. A cardiac myosin inhibitor is a pharmaceutical agent that diminishes myosin activity within the heart muscle, thereby decreasing contraction force. This approach is beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs cardiac function. For instance, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, introduced Camzyos (mavacamten). This stands as the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM), intended to enhance functional capacity and alleviate symptoms. The medication operates as an allosteric and reversible inhibitor specifically targeting cardiac myosin, which leads to a reduction in hypercontractility and left ventricular hypertrophy, alongside an improvement in cardiac filling pressures. This mechanism helps to lessen dynamic left ventricular outflow tract (LVOT) obstruction.
Which Key Players Are Driving Competition In The Ischemic Heart Disease (IHD) Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Download The Full Report For Exclusive Market Findings:
What Are The Key Regional Factors Influencing The Ischemic Heart Disease (IHD) Drugs Market Growth?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Ischemic Heart Disease (IHD) Drugs Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp
Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2025, By The Business Research Company
Antiparasitic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Global Market Report 2025
Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
